Inc280卡马替尼
WebCapmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1. http://drugapprovalsint.com/tag/%d9%83%d8%a7%d8%a8%d9%85%d8%a7%d8%aa%d9%8a%d9%86%d9%8a%d8%a8/
Inc280卡马替尼
Did you know?
WebMay 25, 2024 · 9509 Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who were pretreated (cohort 4) or treatment (tx)-naïve (cohort 5b). Here, we report the efficacy and safety of capmatinib in pts with high-level MET-amplified (gene copy number … WebAug 27, 2024 · 卡马替尼(Capmatinib,INC280)是一种是一种口服的高度选择性的Ia型MET抑制剂,也是FDA批准的首个针对METex14转移性NSCLC的靶向治疗药 …
WebCapmatinib 卡马替尼 Capmatinib(Tabrecta) (INC280) 药物类型:. 适应症: 非小细胞肺癌(NSCLC). 靶点: MET. 是否上市: FDA批准 国内未上市. 研发公司: Novartis(诺华). 说明书:. WebCapmatinib. Molecular Formula CHFNO. Average mass 412.419 Da. Monoisotopic mass 412.144775 Da. ChemSpider ID 25069712.
WebOct 19, 2024 · The most common treatment-related AEs included peripheral edema, nausea, vomiting, and increased blood creatinine levels. Of patients treated with INC280, 83.8% experienced an AE, with 33.1% having grade 3/4 AEs[1],[6]. Capmatinib (INC280) is an investigational, oral and selective MET inhibitor licensed to Novartis by Incyte Corporation … http://www.kangantu.org/tumour/82242.html
WebSynonyms: INCB28060, NVP-INC280, 卡马替尼, INC-280 Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. All …
WebNov 30, 2012 · This study is designed as a Phase II, single arm, open-label, multicenter study to evaluate the safety and efficacy of INC280 as first-line treatment in patients with advanced hepatocellular carcinoma (HCC) who are not eligible for or had disease progression after surgical or locoregional therapies, with c- MET dysregulation. philtrum waxWebAug 20, 2024 · 卡马替尼( inc280 )是一种高效的、选择性的 met 抑制剂,已知可以穿过 bbb,并且先前已经报道了卡马替尼(inc280)的颅内活性。 此处介绍了 … philtrust bank acquired assetsWebAug 27, 2024 · 卡马替尼(Capmatinib,INC280)是一种是一种口服的高度选择性的Ia型MET抑制剂,也是FDA批准的首个针对METex14转移性NSCLC的靶向治疗药物(2024.5),获批的适应症为治疗携带MET外显子14跳跃突变的转移性NSCLC患者,包括一线治疗(初治)患者和先前接受过治疗(经治 ... philtrust bank addressWebFeb 20, 2024 · 2024年5月7日,美国FDA加速批准诺华制药的小分子MET抑制剂Capmatinib(卡马替尼,INC280,商品名Tabrecta)上市,用于治疗携带MET基因外显 … philtrust bank annual reporthttp://www.kangantu.org/tumour/84502.html philtrum typesWeb今天,经过多年的临床前和后期开发,卡马替尼( inc280 )是 fda 批准的一种治疗met外显子 14 跳跃的非小细胞肺癌 (nsclc) 患者的药物。 获得 FDA 批准的旅程始于在细胞系或患 … philtrum swollenWebJun 11, 2015 · The purpose of this study was to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and safety of INC280 alone, and in combination with erlotinib, versus platinum with pemetrexed in the Phase II of this … philtrust bank aurora blvd branch